Dec. 10, 2012
Shanghai Fosun Pharma and Dalian Wanchun Biotech will establish a joint venture to develop innovative oncology treatments. Wanchun has in-licensed China rights to plinabulin, a Class 1.1 innovative anti-tumor drug from Nereus Pharma of the US. Through the JV, Fosun will build Wanchun’s development capability and add potential drugs to its pipeline. Wanchun will serve as an innovative drug incubator for Fosun.